Discovery of potent and selective small-molecule PAR-2 agonists

Journal of Medicinal Chemistry

Volumn 51, Issue 18, 2008, Pages 5490-5493

  Seitzberg, Jimmi Gerner ^a   Knapp, Anne Eeg ^a   Lund, Birgitte Winther ^a   Bertozzi, Sine Mandrup ^a   Currier, Erika A ^b   Ma, Jian Nong ^b   Sherbukhin, Vladimir ^a   Burstein, Ethan S ^b   Olsson, Roger ^a  

^a ACADIA Pharmaceuticals AB   (Sweden)

^b ACAD1A Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AC 264613; AC 55541; AC 98170; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 2 AGONIST; PROTEINASE ACTIVATED RECEPTOR 2 ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; INFLAMMATION; MICROSOME; NONHUMAN; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

DRUG DESIGN; HUMANS; RECEPTOR, PAR-2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 52449126200     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800754r     Document Type: Article

References (19)

1. De Campo, B. A.; Henry, P. J. Protease-Activated Receptors (PARs) are Partly Pro-Inflammatory and Partly Anti-Inflammatory: Will PAR Agonists or Antagonists Participate in Future Drug Therapies. Curr. Drug Targets 2006, 7 (5), 629-637.
2. Macfarlane, S. R.; Seatter, M. J.; Kanke, T.; Hunter, G. D.; Plevin, R. Proteinase-Activated Receptors. Pharmacol. Rev. 2001, 53 (2), 245-282.
3. Ossovskaya, V. S.; Bunnett, N. W. Protease-activated receptors: contribution to physiology and disease. Physiol. Rev. 2004, 84 (2), 579-621.
4. 2-prostanoid EP receptor axis: A potential bronchoprotective unit in the respiratory tract? Eur. J. Pharmacol. 2006, 533, 156-177.
5. D'Agostino, B.; Roviezzo, F.; De Palma, R.; Terracciano, S.; De Nardo, M.; Gallelli, L.; Abbate, G. F.; D'Aiuto, E.; Russo, M.; Cirino, G.; Rossi, F. Activation of protease-activated receptor-2 reduces airways inflammation in experimental allergic asthma. Clin. Exp. Allergy 2007, 37 (10), 1436-1443.
6. (a) McGuire, J. J.; Saifeddine, M.; Triggle, C. R.; Sun, K.; Hollenberg, M. D. 2-Furoyl-LIGRLO-amide: A Potent and Selective Proteinase-Activated Receptor 2 Agonist. J. Pharmacol. Exp. Ther. 2004, 309 (3), 1124-1131.
7. (b) Kawabata, A.; Kanke, T.; Yonezawa, D.; Ishiki, T.; Saka, M.; Kabeya, M.; Sekiguchi, F.; Kubo, S.; Kuroda, R.; Iwaki, M.; Katsura, K.; Plevin, R. Potent and Metabolically Stable Agonists for Protease-Activated Receptor-2: Evaluation of Activity in Multiple Assay Systems in Vitro and in Vivo. J. Pharmacol. Exp. Ther. 2004, 309 (3), 1098-1107.
8. A low potency small molecule PAR-2 antagonist was recently reported. Kelso, E. B.; Lockhart, J. C.; Hembrough, T.; Dunning, L.; Plevin, R.; Hollenberg, M. D.; Sommerhoff, C. P.; McLean, J. S.; Ferrell, W. R. Therapeutic promise of proteinase-activated receptor-2 antagonism in joint inflammation. J. Pharmacol. Exp. Ther. 2006, 316 (3), 1017-1024.
9. (a) Burstein, E. S.; Ott, T: R.; Feddock, M.; Ma, J. N.; Fuhs, S.; Wong, S.; Schiffer, H. H.; Brann, M. R.; Nash, N. R. Characterization of the Mas-related gene family: structural and functional conservation of human and rhesus MrgX receptors. Br. J. Pharmacol. 2006, 147 (1), 73-82.
10. (b) Burstein, E. S.; Piu, F.; Ma, J. N.; Weissman, J. T.; Currier, E. A.; Nash, N. R.; Weiner, D. M.; Spalding, T. A.; Schiffer, H. H.; Del Tredici, A. L.; Brann, M. R. Integrative Functional Assays, Chemical Genomics and High Throughput Screening: Harnessing Signal Transduction Pathways to a Common HTS Readout. Curr. Pharm. Des. 2006, 12 (14), 1717-1729.
11. Burstein, E.; Knapp, A. E. PAR-2 Modulating Compounds and Their Use. Patent WO 2006/127379 A2, 2006.
12. Olsson, R.; Seitzberg, J. G. PAR-2 Modulating Compounds and Their Use. U.S. Patent Application no. 2007/0123508, 2007.
13. Unpublished results.
14. Molecular Operating Environment, Version 2004.03, Chemical Computing Group Inc. (http://www.chemcomp.com), 1010 Sherbrooke Street West, Suite 910, Montreal, Canada H3A 2R7. A number of conformations were generated for each of these two molecules using a stochastic search algorithm and the MMFF94 force field. These conformations were then superimposed in 3D to ensure the maximum overlap of their van der Waals volumes and pharmacophore features, like hydrogen bond donors and acceptors, aromatic rings, and lipophilic moieties. Each resulting alignment was assigned a score which quantified both feature overlap and internal strain energy.
15. Langlois, M.; Guillonneau, C.; Vo Van, T.; Maillard, J.; Lannoy, J.; Nguyen, H. N.; Morin, R.; Manuel, C.; Benharkate, M. Synthèse et propriétés antidépressives de derives de l'amino-2 phényl-4 delta 1-pyrroline. Eur. J. Med. Chem. 1978, 13 (2), 161-169.
16. Relative stereochemistry was assigned by coupling constant analysis and compared to literature values. Evans, D. A.; Mito, S.; Seidel, D. Scope and Mechanism of Enantioselective Michael Additions of 1,3-Dicarbonyl Compounds to Nitroalkenes Catalyzed by Nickel(II) - Diamine Complexes. J. Am. Chem. Soc. 2007, 129, 11583-11592.
17. Cook, G. R.; Stille, J. R. Preparation and 3-Aza-Cope Rearrangement of N-Alkyl-N-allyl Enamines. J. Org. Chem. 1991, 56, 5578-5583.
18. Unpublished results.
19. Gardell, L. R.; Ma, J. N.; Seitzberg, J. G.; Knapp, A. E.; Schiffer, H. H.; Tabatabaei, A.; Davis, C.; Wong, K. K.; Lund, B. W.; Nash, N. R.; Gao, Y.; Lameh, J.; Schmelzer, K.; Olsson, R.; Burstein, E. S. J. Pharmacol. Exp. Ther. 2008, in press.